The Role of High Dose Interleukin-2 in the Era of Targeted Therapy-Reference-Cited by-同舟云学术

The Role of High Dose Interleukin-2 in the Era of Targeted Therapy

Published:2017-09 Issue:3 Volume:198 Page:538-545
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Gills Jessie,Parker William P.,Pate Scott,Niu Sida,Van Veldhuizen Peter,Mirza Moben,Holzbeierlein Jeffery M.,Lee Eugene K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference30 articles.

1. Howlader N, Noone AM, Krapcho M et al: SEER Cancer Statistics Review, 1975-2013, Bethesda: National Cancer Institute April 2016.

2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder Cancer: Version 1. Available at www.nccn.org. Accessed October 24, 2016.

3. A phase I-II study of high-dose recombinant human interleukin-2 in disseminated renal-cell carcinoma;Javadpour;Semin Surg Oncol,1988

4. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma;Lindemann;Cancer Immunol Immunother,1989

5. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study;Bukowski;J Natl Cancer Inst,1990

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy;PLOS ONE;2019-02-20

2. Editorial;Aktuelle Urologie;2018-05-22

3. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma;Current Treatment Options in Oncology;2018-01

4. This Month in Adult Urology;Journal of Urology;2017-09